NCT05257395View on ClinicalTrials.gov

A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

397

Participants

Timeline

Start Date

March 14, 2022

Primary Completion Date

December 5, 2025

Study Completion Date

September 5, 2030

Conditions
Advanced Breast Cancer
Interventions
DRUG

XZP-3287+ Letrozole/Anastrozole

XZP-3287 360 mg orally after meals Twice daily of every 28-day cycle; Letrozole tablets 2.5mg orally once daily of every 28-day cycle or Anastrozole tablets 1mg orally once daily of every 28-day cycle

DRUG

Placebo + Letrozole/Anastrozole

Placebo 360 mg orally after meals Twice daily of every 28-day cycle; Letrozole tablets 2.5mg orally once daily of every 28-day cycle or Anastrozole tablets 1mg orally once daily of every 28-day cycle

Trial Locations (1)

150081

Harbin Medical University Cancer Hospital, Harbin

All Listed Sponsors
lead

Xuanzhu Biopharmaceutical Co., Ltd.

INDUSTRY